Abata Therapeutics' ABA-101 Gets the US FDA FTD to Treat Progressive Multiple Sclerosis (MS)
Shots:
- Based on an in vivo preclinical trial, the US FDA has granted fast-track designation to the company’s ABA-101 to treat progressive MS
- In trial, the drug was well tolerated and demonstrated antigen-dependent Treg functionality, increased anti-inflammatory cytokine production, reduced inflammatory cytokine production, and therapeutic effects
- ABA-101 is an autologous Treg therapy using the patient’s own Tregs to express a T cell receptor (TCR) that specifically targets immunogenic myelin fragments in the CNS, providing a favorable safety profile and localized anti-inflammatory effects at the disease site. Recently, the drug received IND approval, and the company plans to initiate its P- I trial
Ref: Abata Therapeutics | Image: Abata Therapeutics
Related Posts:- Abata Therapeutics Reports the US FDA’s IND Clearance for P-I Trial of ABA-101 for Progressive Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
